Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
New nano approach could cut dose of leading HIV treatment in half

Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.

Published
22 hours ago
From
University of Liverpool press release
Darunavir Associated with Heart Disease

But atazanavir use in HIV patients not linked to cardiovascular disease.

Published
20 February 2017
From
MedPage Today HIV/AIDS
Merck's lead HIV play hits the mark in first phase 3 challenge

Merck has taken a big step toward getting its lead HIV candidate doravirine to market, setting up a showdown with Johnson & Johnson's big-selling Prezista.

Published
19 February 2017
From
FierceBiotech
New NNRTI doravirine shows good efficacy in phase 3 study

Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) from Merck, reduced HIV viral load as well as boosted darunavir in a phase 3 clinical trial of

Published
19 February 2017
By
Liz Highleyman
Time spent by US HIV patients in care with a transmissible viral load has fallen by three-quarters since 2000

A study by the US Centers for the Disease Control (CDC) presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2017) in Seattle found that

Published
18 February 2017
By
Gus Cairns
Spanish vaccine induces viral control off ART in nearly 40% of recipients

A so-called ‘HIV Conserv’ vaccine has, for the first time, produced significant prolonged viral control in a large minority of recipients once they were taken off antiretroviral therapy

Published
17 February 2017
By
Gus Cairns
Tenofovir/emtricitabine/efavirenz less likely to cause adverse birth outcomes than other regimens, Botswana study finds

Infants exposed to an antiretroviral regimen of tenofovir, emtricitabine and efavirenz (Atripla) from conception experienced fewer adverse birth outcomes compared to other three-drug regimens, according to a study

Published
16 February 2017
By
Carole Leach-Lemens
Experimental STI prophylaxis in PrEP users produces big drops in syphilis and chlamydia infections but not in gonorrhoea

Use of the antibiotic doxycycline as on-demand post-exposure prophylaxis by men who have sex with men (MSM) taking part in the Ipergay HIV pre-exposure prophylaxis (PrEP)

Published
15 February 2017
By
Gus Cairns
Turning the tide on HIV in Zimbabwe, one AIDS denialist at a time

How does a country—with a history of AIDS-denialism in government, and a financial crisis spanning 10 years—turn the tide on AIDS?

Published
15 February 2017
From
BETA blog
Changes in viral suppression over time reveal disparities in HIV care in the United States

Sustained viral suppression over the course of a year may be a better measure than the most recent viral load test result when it comes to understanding

Published
15 February 2017
By
Liz Highleyman
← First12345...437Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.